The company maintains a conservative debt-to-equity ratio of 0.07 as of 2026Q1, though this is overshadowed by an accumulated deficit in retained earnings that has reached $461.5 million.
| Total Current Assets | 46.32M | 58.05M | 68.33M | 179.18M | 117.82M | 176.56M | 62.22M | 265K |
| Cash & Short-Term Investments | 44.69M | 55.81M | 58.28M | 176.87M | 113.05M | 173.52M | 61.7M | 239K |
| Cash Only | 44.69M | 55.81M | 58.28M | 176.87M | 111.9M | 145.74M | 61.7M | 239K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 1.15M | 27.78M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.63M | 2.24M | 10.05M | 2.31M | 4.77M | 0 | 0 | 0 |
| Total Non-Current Assets | 67K | 522K | 11.61M | 20.75M | 11.49M | 9.14M | 303K | 0 |
| Property, Plant & Equipment | 67K | 153K | 10.62M | 14.87M | 7.99M | 5.69M | 291K | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 738K | 369K | 0 | 0 | 0 | 1.88M | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 988K | 5.87M | 3.5M | 1.58M | 12K | 0 |
| Total Assets | 46.38M | 58.57M | 79.94M | 199.93M | 129.31M | 185.71M | 62.53M | 265K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Asset Growth % | -138.77% | -26.73% | -60.02% | 54.61% | -30.37% | 197% | 23494.72% | - |
| Total Current Liabilities | 9.29M | 11.1M | 21.67M | 22.86M | 19.1M | 4.64M | 1.62M | 286K |
| Accounts Payable | 4.61M | 3.23M | 12.93M | 6.85M | 6.83M | 1.33M | 727K | 271K |
| Days Payables Outstanding | 3.48K | 837.51 | - | - | - | - | 2.01K | - |
| Short-Term Debt | 1.24M | 0 | 0 | 0 | 0 | 0 | 36K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.44M | 6.41M | 203K | 192K | 636K | 480K | 0 | 0 |
| Current Ratio | 4.98x | 5.23x | 3.15x | 7.84x | 6.17x | 38.08x | 38.43x | 0.93x |
| Quick Ratio | 4.98x | 5.23x | 3.15x | 7.84x | 6.17x | 38.08x | 38.43x | 0.93x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 18.37M | 17.92M | 6.69M | 7.83M | 1.67M | 2.29M | 55.74M | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 12.52M | 128K | 6.69M | 7.83M | 1.67M | 2.29M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 18.37M | 17.79M | 0 | 0 | 0 | 0 | 55.74M | 0 |
| Total Liabilities | 27.67M | 29.02M | 28.36M | 30.69M | 20.77M | 6.92M | 57.36M | 286K |
| Total Debt | 1.24M | 1.59M | 8.77M | 10.3M | 2.29M | 2.85M | 259K | 0 |
| Net Debt | -43.45M | -54.22M | -49.51M | -166.57M | -109.61M | -142.89M | -61.44M | -239K |
| Debt / Equity | 0.07x | 0.05x | 0.17x | 0.06x | 0.02x | 0.02x | 0.05x | - |
| Debt / EBITDA | -0.02x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.66x | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | 18.72M | 29.55M | 51.57M | 169.24M | 108.54M | 178.78M | 5.17M | -21K |
| Equity Growth % | -230.54% | -42.7% | -69.53% | 55.92% | -39.29% | 3358.75% | 24714.29% | - |
| Book Value per Share | 0.26 | 0.57 | 1.43 | 4.96 | 3.71 | 7.49 | 0.48 | -0.00 |
| Total Shareholders' Equity | 18.72M | 29.55M | 51.57M | 169.24M | 108.54M | 178.78M | 5.17M | -21K |
| Common Stock | 7K | 7K | 4K | 4K | 3K | 3K | 1K | 1K |
| Retained Earnings | -461.46M | -449.05M | -387.25M | -248.82M | -131.57M | -49.74M | -8.18M | -2.85M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | -1K | -10K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital runway exhaustion risk
As reported in financial statements, Biomea Fusion's total assets have contracted significantly from $199.9 million in 2023Q4 to $46.4 million by 2026Q1, reflecting a consistent and aggressive depletion of resources as the company funds its intensive clinical development pipeline without any offsetting commercial revenue streams.
The downward trajectory of the balance sheet suggests that the company is nearing a critical inflection point where external financing will be required to maintain operations. This persistent decline in asset value indicates that the business model remains entirely dependent on capital market access rather than internal value creation.
Based on the most recent 2026Q1 data, the company's cash position has dwindled to $44.7 million, a sharp reduction from the $176.9 million reported in 2023Q4, which highlights the accelerating pressure on the firm's ability to sustain its ongoing clinical trial activities without immediate capital infusion.
While the current ratio of 4.98 appears superficially healthy, it masks the reality of a high burn rate that is rapidly consuming the remaining cash runway. Investors should monitor the company's ability to secure non-dilutive funding, as the current liquidity buffer may be insufficient to reach key clinical milestones.
According to historical balance sheet data, retained earnings have plummeted to a deficit of $461.5 million as of 2026Q1, illustrating the profound impact of sustained operating losses on the company's equity base and the resulting reliance on external financing to maintain a positive book value.
The erosion of equity quality suggests that the company's value is almost entirely speculative, tied to the future success of its clinical pipeline rather than tangible assets. This structure implies that any further delays in clinical trials could lead to significant shareholder dilution as the company seeks to replenish its capital.
As indicated by the 2026Q1 figures, the company maintains a conservative debt-to-equity ratio of 0.07, suggesting that management has avoided significant debt financing, likely due to the lack of stable cash flows required to service interest obligations in a high-cost clinical development environment.
The low debt levels appear to be a necessity rather than a strategic choice, as the company lacks the operational cash flow durability to support traditional leverage. This reliance on equity-based funding models may indicate that the company is effectively closed off from debt markets until it achieves a major clinical success.
Quick answers to the most common questions about buying BMEA stock.
As of 2025, Biomea Fusion, Inc. (BMEA) had total assets of $58.6M including $58.0M in current assets.
Biomea Fusion, Inc. (BMEA) carries total debt of $1.6M, offset by $55.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Biomea Fusion, Inc. (BMEA) has total shareholders' equity (book value) of $29.6M ($0.57 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Biomea Fusion, Inc. (BMEA) reported a current ratio of 5.23x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.